Find Academic Supervisors

Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.

• Stem Cell Biology
• Genetic Engineering
• Epigenetics
• +5 more

Jerry W. Shay is a Professor in the Department of Cell Biology at UT Southwestern Medical Center, holding the Southland Financial Corporation Distinguished Chair in Geriatric Research. He also serves as Associate Director for Education and Training at the Harold Simmons Comprehensive Cancer Center. His research focuses on telomere biology, aging, and cancer therapy development, with an emphasis on targeting telomerase in cancer treatment and understanding age-related disease mechanisms. Shay earned his BA in Zoology/Cell Biology from the University of Texas at Austin (1966), MA in Cell Biology from the University of Kansas (1968), and PhD in Developmental Biology from the University of Colorado Boulder (1975). He joined UT Southwestern in 1975, advancing from Assistant/Associate Professor to full Professor in 1993. His research interests include telomere dysfunction-induced anti-tumor immunity, cancer therapy resistance, and the role of telomerase in cellular aging. Key projects involve developing therapies like 6-thio-dG, which targets telomerase-dependent cancers, and studying the interplay between environmental toxins and colorectal carcinogenesis. Awarded numerous honors including the UT Regent’s Outstanding Teaching Award (2012) and the Piper Professorship (2013), Shay has contributed to over 30 patents, including methods to detect telomerase activity and compounds targeting cancer cell adhesion. His lab collaborates with companies like Maia Biotechnology and Reata Pharmaceuticals to translate research into clinical applications. Shay’s work bridges basic science and translational research, with ongoing projects in radiation-induced cancer progression, immune modulation in cancer treatment, and telomere measurement technologies like the TeSLA assay.

• Aging Research
• Cancer Biology
• Telomere Biology
• +3 more

Huaiying Zhang is an Assistant Professor in the Department of Biological Sciences at Carnegie Mellon University, part of the Mellon College of Science. His research focuses on the role of biomolecular condensates in cellular functions and cancer progression, particularly investigating phase transitions in telomere maintenance and cancer cell immortality. He holds a Ph.D. from McGill University and completed postdoctoral research at Dartmouth College, Princeton University, and the University of Pennsylvania. Research interests include engineering synthetic organelles, developing optogenetic tools to manipulate phase separation in live cells, and targeting phase transitions for cancer therapy. His work bridges biophysics, cell biology, and synthetic biology to address fundamental questions in nuclear organization and disease mechanisms. Education: Ph.D., McGill University Postdoctoral Fellowships: Dartmouth College, Princeton University, University of Pennsylvania Publications highlight advances in understanding telomere clustering in cancer cells, nuclear body formation, and applications of phase separation in therapeutic strategies. Collaborative projects emphasize interdisciplinary approaches, combining experimental and theoretical methods. Lab activities focus on biomolecular condensates' material properties, their roles in genomic processes, and translational applications in cancer treatment. The lab actively seeks students and researchers interested in cellular biophysics and disease biology.

• Biomolecular Condensates
• Cancer Biology
• Cellular Functions
• +3 more

Dr. Seth Guller is a Senior Research Scientist and Director of the Gyn/Endocrine Laboratory at the Yale School of Medicine. He specializes in reproductive sciences, focusing on placenta diseases, pre-eclampsia, and pregnancy outcomes. His research integrates biochemistry and clinical laboratory techniques to improve patient care, particularly through advanced hormone analysis using the Roche Cobas e411 analyzer. Dr. Guller holds a PhD from Mount Sinai School of Medicine (1986) and has authored over 75 peer-reviewed publications. Affiliations: Yale Fertility Center, Reproductive Endocrinology & Infertility Division, Perinatal Research Group Key Research Areas: Placental biology, maternal-fetal immune interactions, viral infections in pregnancy, and cytokine regulation in reproductive health. His laboratory has pioneered studies on mechanisms underlying preeclampsia, Zika virus vertical transmission, and the impact of maternal obesity on placental function. Collaborations with clinicians like Dr. Charles Lockwood and Dr. Harvey Kliman highlight translational research bridging basic science and clinical care. Recent publications (2020–2023) emphasize placental immunology, SARS-CoV-2 effects on pregnancy, and metabolic pathways influencing fetal development. His work has advanced understanding of Hofbauer cell functions, cytokine signaling, and viral pathogenesis in obstetrical contexts.

• Obstetrics
• Gynecology
• Placenta Diseases
• +5 more

Rodney J. Taylor is a Professor and Chair of the Department of Otorhinolaryngology-Head & Neck Surgery at the University of Maryland School of Medicine. With clinical expertise in head and neck cancer management, skull base surgery, and endocrine surgery, he has led national-recognized research initiatives since joining the faculty in 2001. As Chief of Otolaryngology at the Baltimore Veteran’s Administration Medical Center, he combines clinical excellence with scientific innovation. Education : MD from Harvard Medical School (1995), MPH from University of Michigan School of Public Health (1999) Training : Residency in Otolaryngology-Head & Neck Surgery at University of Michigan (1995-2001) Dr. Taylor's research focuses on improving head and neck cancer survival through immune-cytotoxicity studies, SCCHN cell line analysis, xenograft models, and clinical trials. His collaborations with Dr. Zalzman's lab explore cancer stem cell immortality mechanisms and regenerative medicine advancements. Current research also investigates NK cell FcγRIIIa polymorphisms for personalized antibody therapy. Scientific achievements include developing the Neck Dissection Impairment Index and recognition as a top otolaryngologist. His lab secures funding from NIH, DOD, and philanthropic sources like the Orokawa Foundation and Weitzman family. Research trends emphasize translational oncology, immunotherapy, and stem cell applications in head and neck diseases. Scientific Awards : Ranked among 'America’s Top Otolaryngologists'

• Head and Neck Surgical Oncology
• Rhinology and Sinus Disease
• Endocrine Surgery
• +7 more

Dr. Stephanie Panier serves as a Max Planck Research Group Leader at the Max Planck Institute for Biology of Ageing in Cologne, Germany, and as a Principal Investigator at the Institute for Genome Stability in Aging and Disease within the Medical Faculty of the University of Cologne. Her research program investigates the fundamental mechanisms by which cells maintain genome stability through sophisticated DNA damage response pathways. Her academic journey includes: PhD in Molecular Genetics from the University of Toronto (2008-2013) under Prof. Daniel Durocher Postdoctoral training at the Francis Crick Institute in London (2013-2019) with Prof. Simon Boulton Undergraduate studies in Biology at Ruprecht-Karls-Universität Heidelberg, Germany (2001-2006) Dr. Panier's laboratory focuses on two central questions in genome stability research: how DNA damage response pathways interact with telomere maintenance mechanisms, and how RNAs and RNA-binding proteins organize chromatin-based responses to DNA lesions. Her team employs cutting-edge cell biological and omics approaches to identify and characterize RNA-binding proteins at DNA damage sites, mapping their chromatin dynamics and interactions following genotoxic stress. This research has significant implications for understanding aging-associated diseases driven by genomic instability, including cancer and neurodegeneration. Analysis of her publication record reveals consistent contributions to understanding DNA repair mechanisms, with recent work expanding into cancer biology, telomere maintenance in alternative lengthening pathways, and the emerging role of RNA metabolism in genome stability. Her scientific achievements have been recognized through: Vivash Award for best PhD thesis (2013) FEBS Excellence Award (2023) EMBO Long-Term Fellowship (2013-2014) Vanier Canada Graduate Scholarship (2010-2013) Boehringer Ingelheim Fonds PhD Fellowship (2008-2010) EIRR21st Fellowship (2023) Dr. Panier actively contributes to the scientific community through leadership roles including Vice Coordinator of the DFG Research Unit FOR5504 (2023-2026), membership on the advisory board of the German Society for Research on DNA Repair since 2022, and representation on the Biology and Medicine Section of the Max Planck Society's scientific council since 2022. She also serves as a Principal Investigator in the Cologne Excellence Cluster 'Cellular Stress Responses in Aging-Associated Diseases' (CECAD). Her laboratory comprises postdoctoral researchers and PhD students working collaboratively to advance our understanding of genome stability mechanisms in aging, with current projects focusing on RNA-binding proteins in DNA damage response and telomere maintenance pathways.

• Genome Stability
• DNA Damage Response
• Aging Research
• +4 more

Jefferson W. Kinney is a Professor and Founding Chair of the Department of Brain Health at the Kirk Kerkorian School of Medicine, University of Nevada Las Vegas (UNLV) . He co-directs both the Pam Quirk Brain Health and Biomarker Laboratory and the Translational Mechanisms and Drug Discovery Laboratory , focusing on neurodegenerative diseases. Colorado State University - PhD National Institute of Mental Health - Intramural Research Training Fellowship The Scripps Research Institute - Helen Dorris Fellowship Dr. Kinney's research spans cellular and molecular mechanisms of Alzheimer's disease , with emphasis on: Neuronal-glial interactions in AD pathogenesis Role of GABA B receptors in memory deficits Diabetes-induced AD risk (insulin signaling, hyperglycemia) Neuroinflammatory pathways in AD and traumatic brain injury (TBI) Translational biomarker discovery in clinical samples GPCR signaling in microglial activation His publications reveal a focus on GABAergic dysfunction , metabolic comorbidities , and translational models bridging preclinical and clinical AD research. Key techniques include: Transgenic mouse models (APP/PS1) Cellular/molecular biology (qRT-PCR, Western blot) Behavioral assays (Barnes maze, fear conditioning) Immortalized microglia cultures (BV2 cells) Scientific Honors: Reg Grundy and Joy Chambers-Grundy Chair for Brain Health Helen Dorris Fellowship in Neuropharmacology NIMH Intramural Research Training Fellowship Dr. Kinney leads two interconnected laboratories that synergize preclinical mechanisms ( Translational Mechanisms and Drug Discovery Laboratory ) with clinical biomarker discovery ( Pam Quirk Brain Health and Biomarker Laboratory ).

• Alzheimer's disease
• Neurodegenerative disorders
• Cellular and molecular mechanisms
• +5 more

Paul M. Lieberman, Ph.D. serves as the Hilary Koprowski, M.D., Endowed Professor and Program Leader of the Genome Regulation and Cell Signaling Program at the Ellen and Ronald Caplan Cancer Center of The Wistar Institute. He also directs The Wistar Institute Center for Chemical Biology & Translational Medicine, which he founded in 2010. Lieberman joined The Wistar Institute in 1995 as an assistant professor and has established himself as a leading researcher in viral oncology, with continuous publication activity through 2025. Lieberman earned his bachelor's degree in chemistry from Cornell University and completed his doctorate in pharmacology/virology at The Johns Hopkins University School of Medicine, followed by postdoctoral training at the University of California, Los Angeles. His research focuses on how cancer-associated viruses, particularly Epstein-Barr virus (EBV) and Kaposi's Sarcoma Associated Herpesvirus (KSHV), establish latent infections that can lead to cancer or autoimmune disorders. His laboratory investigates epigenetic controls of viral latency, virus modulation of host chromosomes, chromosome conformation control of viral latency, telomere maintenance in cancer, and drug discovery targeting viral proteins. Recent publications reveal Lieberman's research trends spanning molecular virology, epigenetics, and translational applications. His work shows strong emphasis on viral persistence mechanisms, the connection between EBV infection and multiple sclerosis, and development of small molecule inhibitors targeting viral proteins like EBNA1. This research bridges fundamental virology with clinical applications for treating virus-associated cancers and autoimmune conditions. Epstein-Barr virus and multiple sclerosis. Nat Rev Microbiol. 2023. Multiple sclerosis patient-derived spontaneous B cells have distinct EBV and host gene expression profiles in active disease. Nat Microbiol. 2024. Therapeutic approaches to Epstein-Barr virus cancers. Curr Opin Virol. 2022. Lieberman leads a substantial research team including Research Associate Professor Troy Messick, Senior Staff Scientist Samantha Soldan, multiple staff scientists, postdoctoral fellows, pre-doctoral trainees, and research assistants. His laboratory receives significant funding for viral oncology research and collaborates with structural biologists and medicinal chemists to advance drug discovery. The laboratory actively utilizes The Wistar Institute's Molecular Screening Facility for high-throughput compound screening. The Lieberman Laboratory maintains strong connections with clinical researchers studying EBV-associated diseases and multiple sclerosis, positioning his work at the intersection of basic science and clinical translation. His research on small molecule inhibitors of EBNA1 represents a promising therapeutic avenue for EBV-associated malignancies.

• Virology
• Cancer Research
• Epstein-Barr Virus
• +5 more

Professor Hilda Pickett is Head of the Telomere Length Regulation Unit at the Children's Medical Research Institute (CMRI) and holds a conjoint professorship at the University of Sydney. Her research focuses on telomere biology, particularly the molecular mechanisms of telomere length control, genomic stability, and cellular immortality in cancer. PhD, University of Leicester, UK Postdoctoral experience: Cancer Research UK (Leeds) and CMRI, Australia Research Highlights: Mechanisms of Alternative Lengthening of Telomeres (ALT) in cancer cells Telomere replication stress and its role in disease Development of telomere-specific therapeutic strategies Investigations into RNA-binding proteins in telomerase activity Recent Publications demonstrate expertise in telomere dynamics, DNA repair pathways, and cancer genomics across multiple journals like Nature Structural and Molecular Biology and Science . Key trends include targeting ALT mechanisms for cancer therapy, telomere stress markers, and genomic instability in sarcomas. Scientific Grants include funding from the US Department of Defence, Australian Department of Health, and NHMRC for projects like "Prevention of bone marrow failure in Fanconi anemia" and "Alternative Lengthening of Telomeres (ALT): Target Discovery to Treatment." Students advised include Deborah Nazareth: Recombinant AAV vector design for hepatocellular carcinoma Jake Schwenke: Synthetic lethality with FANCM inhibition in ALT-negative cancers

• Telomere Biology
• Cancer Genetics
• Genomic Stability
• +3 more

David E. Housman is a Professor of Biology at the Massachusetts Institute of Technology (MIT) and a Virginia & D.K. Ludwig Scholar for Cancer Research. He holds the Ludwig Professorship in Biology and leads the Housman Lab at the Koch Institute for Integrative Cancer Research. His research focuses on genetic mechanisms underlying Huntington’s disease, cancer, and cardiovascular disease, with particular emphasis on developing therapeutic strategies for intervention. Education: B.A. in Biology from Brandeis University (1966) Ph.D. in Biology from Brandeis University (1971) Research Interests: Dr. Housman’s work integrates genetic approaches to understand disease mechanisms. Key areas include: Modifier genes in Huntington’s disease pathogenesis Genetic pathways in cancers like Wilms tumor, glioblastoma, and melanoma Cardiovascular disease mechanisms via genetic and proteomic analyses His lab investigates transcriptional dysregulation, small molecule therapies, and protein aggregation in neurodegenerative diseases. Publications: Over 150 peer-reviewed articles, with recent focus on multi-omic analyses of Huntington’s disease and therapeutic targeting of epigenetic modifications. Awards & Honors: Fellow of the American Association for the Advancement of Science (1988) Fellow of the American Academy of Microbiology (1994) Member of the National Academy of Sciences and Institute of Medicine (2004) Scientific Contributions: Co-founded Genzyme Genetics and Integrated Genetics Adviser to Kenna Technologies and Variagenics Inc. His lab collaborates on projects ranging from modifier gene identification to clinical trials for Huntington’s disease therapies. Labs & Teams: The Housman Lab includes researchers, postdocs, and students studying genetic and molecular mechanisms of disease. Key personnel include Dr. Julia Alberta and Dr. Ferah Yildirim.

• Precision medicine
• Huntington's disease
• Cancer biology
• +2 more

Professor Rhona Anderson is a leading academic in Radiation Biology at Brunel University London, affiliated with the Department of Life Sciences under the College of Health, Medicine and Life Sciences . As a Professor and Director of the Centre for Health Effects of Radiological and Chemical Agents , she leads research into the genomic and health impacts of ionizing radiation. Qualifications: PhD, MSc, and BSc (Hons) in life sciences-related fields, with professional certification as a Clinical Cytogeneticist . Research Interests focus on radiation cytogenetics , low-dose radiation effects , and genetic biomarkers of radiation exposure . Her work extends to veterans' health , occupational radiation risks , and mechanisms of DNA damage . Trends in Recent Publications highlight her expertise in chromosome aberration analysis , intergenerational radiation effects , and biomarker development for radiation exposure. Her studies span medical , environmental , and occupational radiation sources , using advanced techniques like M-FISH and germline mutation analysis . Scientific Awards: 2023: Elected Vice-President, International Association for Radiation Research 2017: Honorary Membership, Royal College of Radiology, UK Advising and Grants include leadership of the Centre for Health Effects of Radiological and Chemical Agents and supervision of PhD projects on radiation health risks. While specific grant details are not listed, her extensive publication record reflects sustained research funding. Labs and Teams include the Centre for Health Effects of Radiological and Chemical Agents and collaboration with the IEHS (Institute of Environment, Health and Societies) research group.

• Radiation Biology
• Radiation Cytogenetics
• Low Dose Radiation Research
• +3 more

Chantal Autexier is a Professor in the Department of Anatomy and Cell Biology at McGill University, affiliated with the Lady Davis Institute for Medical Research and Jewish General Hospital. Her work centers on telomere biology, focusing on telomerase regulation and its role in cancer cell immortalization, genome integrity, and premature aging disorders like dyskeratosis congenita. Using cell culture models, she investigates telomere maintenance mechanisms and their implications in disease. BSc (Concordia University), PhD (McGill University) Her recent research explores telomerase-telomere interactions, epigenetic regulation (e.g., R-2-hydroxyglutarate and KDM4A), and the impact of dyskerin mutations on telomerase function. Articles from 2019–2025 emphasize molecular biology, cancer therapeutics, and aging-related pathways, with sub-fields spanning DNA repair, replication stress, and RNA-protein dynamics. She also contributes to geroscience initiatives, such as the Canadian Translational Geroscience Network (2025). Her lab employs advanced techniques in cell imaging and molecular genetics to study telomere integrity in cancer and aging diseases.

• Telomere Biology
• Cancer Research
• Genome Integrity
• +3 more

Ahmet Hoke, MD, PhD, is a Professor of Neurology and Neuroscience at the Johns Hopkins University School of Medicine, where he also serves as Director of the Neuromuscular Division. His work bridges clinical neurology and translational neuroscience, focusing on peripheral nervous system disorders. Dr. Hoke's research centers on the mechanisms of peripheral neuropathies and nerve regeneration. His laboratory investigates conditions such as HIV-associated sensory neuropathy, chemotherapy-induced neuropathy, and diabetic neuropathy. Using both in vitro and in vivo models, his team explores axonal degeneration and regeneration, with a focus on Schwann cell biology and the development of nanofiber-based nerve grafts. His work also includes engineering stem cells for gene delivery to enhance nerve repair in chronic denervation scenarios, such as those seen in ALS and inherited neuropathies. The recent publications highlight a strong focus on nerve regeneration, neuropathic mechanisms, and innovative therapeutic strategies. His work spans molecular neuroscience, bioengineering, and clinical neurology, reflecting a multidisciplinary approach to treating peripheral nerve disorders. Scientific Awards: No specific awards mentioned in the provided text. Dr. Hoke actively mentors graduate students, postdoctoral fellows, and research staff, contributing significantly to training the next generation of neuroscientists. His lab includes MD/PhD students and research associates engaged in diverse projects. While grant details are not listed, his sustained research output and lab structure suggest active funding. His collaborative work includes partnerships across neurology, oncology, radiology, and bioengineering disciplines. Dr. Hoke leads an active research laboratory focused on peripheral nerve repair. The lab includes postdoctoral fellows, graduate students, and research technicians working on molecular mechanisms of neuropathy and regenerative strategies. The team utilizes advanced models of nerve injury and employs techniques in molecular biology, cell therapy, and biomaterials to develop novel treatments for nerve damage.

• Neuroscience
• Peripheral Neuropathy
• Axonal Regeneration
• +9 more

Anja Groth, 43 years old, is a full professor at the Biotech Research and Innovation Centre (BRIC) under the University of Copenhagen's Faculty of Health Sciences. Her research centers on molecular cell biology, epigenetics, DNA repair, and genome stability, with significant contributions to understanding how cells maintain functional memory during division—a critical process for both human development and cancer progression. Education: MSc in Biochemistry, University of Copenhagen PhD in Cancer Biology, University of Copenhagen (2004) Postdoc at Institut Curie, Paris (3 years) Her groundbreaking work on DNA repair mechanisms revealed a protein critical for cancer cell survival through error-free DNA repair. This discovery is paving the way for novel cancer therapies that block this protein. Using advanced molecular biology and interdisciplinary collaboration, she has published in top journals like Nature and secured two major ERC grants. Key Research Themes: Epigenetic memory and chromatin replication DNA damage repair pathways Histone dynamics and inheritance Replication fork stability Protein networks in genome maintenance Articles show a consistent focus on histone chaperones, ubiquitination pathways, and chromatin assembly factors. Her 2016 discovery of H4K20me0 marks and the TONSL–MMS22L complex has had lasting impacts on DNA repair research. Awards & Grants: EliteForsk Award (2018) EMBO Investigator Heirloom Award for Women Scientist Leaders ERC Starting Grant ERC Consolidator Grant As leader of a diverse research group of 15 international scientists (primarily women), Groth emphasizes collaborative innovation and trust-building in scientific environments. She advocates for sustainable lab practices and flexible research strategies that allow unexpected discoveries.

• Molecular Cell Biology
• Epigenetics
• DNA Repair
• +3 more

Dr. David Earnest is a Professor in the Department of Neuroscience and Experimental Therapeutics at the Texas A&M University College of Medicine and serves as an executive member of the Texas A&M University Center for Biological Clocks Research. He earned his Master of Science degree in 1979 and Doctoral degree in 1984 from Northwestern University. His research centers on the neurobiology of circadian rhythms , investigating how disruptions in biological clocks contribute to human health disorders including obesity, diabetes, cardiovascular disease, stroke, Alzheimer's Disease, Fetal Alcohol Syndrome, sleep-wake disturbances, and depression. Using multidisciplinary approaches, he examines molecular pathways linking circadian dysregulation to disease pathogenesis, with particular emphasis on shift work , aging , and sex differences . Analysis of his recent publications reveals a strong trajectory toward understanding immune-circadian interactions in cognitive decline and stroke outcomes, with increasing focus on sex-specific responses to circadian disruption and the role of inflammatory mediators in metabolic and neurodegenerative diseases. Dr. Earnest leads a laboratory renowned for developing immortalized SCN cell lines to study the mammalian circadian pacemaker. His current work investigates how shift-work schedules exacerbate brain injury and functional deficits following ischemic stroke, integrating molecular, cellular, and behavioral approaches to address critical gaps in chronobiology and public health.

• Circadian Rhythms
• Neurobiology
• Sleep Disorders
• +6 more